glp-faq
All FAQs
FAQstarting

Should I wait for retatrutide instead of starting tirzepatide?

Retatrutide won't be available for at least 1–2 more years. Here's what the wait actually costs metabolically and whether the marginal gain is worth it.

Updated May 21, 2026 · 3 min read

No — for most people, waiting for retatrutide while declining tirzepatide is a bad trade. The weight loss difference between the two drugs is real but modest, and the metabolic cost of waiting 1–2 years while retatrutide completes its approval process is not.

That said, the logic of "wait for the better drug" isn't obviously wrong — it just doesn't hold up when you run the numbers.

The approval timeline is not short

As of 2026, retatrutide is in phase 3 trials. Eli Lilly has not announced an NDA submission date. Even under an optimistic scenario — phase 3 data available, NDA filed promptly, priority review — the earliest realistic commercial availability is late 2026 or 2027. And that's in the US; other markets will be later.

Phase 3 trials sometimes take longer than expected. NDA reviews have delays. Manufacturing scale-up and launch can lag approval. The prudent planning assumption is 1–2 more years minimum, with significant uncertainty on the upside.

What the wait costs

Metabolic disease isn't static. While you wait:

  • Weight continues to accumulate, or stays elevated, with its associated effects on blood pressure, joint load, insulin resistance, and sleep
  • Cardiovascular risk accumulates — the SELECT trial demonstrated that being on semaglutide for 3 years reduced MACE by 20%. Every year off treatment is a year without that protective effect
  • Comorbidities advance — type 2 diabetes, fatty liver disease, and sleep apnea are all progressive conditions that are meaningfully improved by the weight loss tirzepatide achieves

If retatrutide produces, say, 24% weight loss versus tirzepatide's 22.5% — a 1.5-percentage-point difference — that delta translates to about 2–3 lbs on a 200-lb person. Starting tirzepatide today and achieving 22.5% weight loss over 72 weeks while you wait for retatrutide availability is almost certainly a better outcome than waiting.

The switching option exists

This is the most underappreciated point: you don't have to choose between drugs permanently.

If you start tirzepatide now, achieve meaningful weight loss, and retatrutide becomes available and is clearly superior, you can switch. The drugs work through overlapping but distinct mechanisms, and switching from one GLP-1-class drug to another is already common clinical practice (people switch from semaglutide to tirzepatide frequently). Switching from tirzepatide to retatrutide would follow the same logic.

Starting tirzepatide doesn't lock you out of retatrutide. It just means you get 1–2 years of active treatment rather than 1–2 years of waiting.

When waiting might make sense

There are some narrow scenarios where waiting has a real argument:

  • You're at the end of a long titration on semaglutide with modest response, and your prescriber has already discussed escalating. If retatrutide's approval is genuinely imminent (an NDA is under review, for instance), waiting a few months rather than switching twice might make sense.
  • You have specific contraindications to tirzepatide that might not apply to retatrutide. This is unlikely but possible.
  • You're in a clinical trial for retatrutide. If you can enroll, that's access to the drug now, not later, with medical supervision.

These are exceptions, not the default.

The phase 3 uncertainty factor

One additional consideration: phase 3 trials frequently produce more modest results than phase 2, as the participant population broadens, entry criteria change, and the "halo effect" of small trials washes out. Retatrutide's 22.8% at 12 mg in 338 people may not hold in a 5,000-person trial with broader inclusion criteria.

This isn't a prediction that retatrutide will underperform — but it is a reason not to treat the phase 2 headline number as a guarantee.

The drug is promising. Waiting for it when you have meaningful metabolic disease right now is not a sound strategy.